Medipost
Scope
Date
~
-
Bio & Pharma
Medipost completes first dose of Cartistem in phase 3 clinical trials in Japan
South Korea's stem cell research company Medipost Co. said on Monday that it has completed the administration of Cartistem, a stem cell treatment fo...
Jan 17, 2023 (Gmt+09:00)
-
Bio & Pharma
Medipost's Cartistem shows effects on patellar cartilage defect patients
Medipost's knee osteoarthritis treatment Cartistem has been mentioned in a renowned international journal, showing that it is effective even in pati...
Dec 27, 2022 (Gmt+09:00)
-
Bio & Pharma
Medipost, OmniaBio to enhance cooperation for CDMO business
South Korea's stem-cell therapy company Medipost announced on Thursday that its Canadian affiliate OmniaBio made a two-day visit to South Korea on N...
Dec 01, 2022 (Gmt+09:00)
-
Bio & Pharma
Medipost to expand CDMO business with 10 new clean rooms in Korea
Medipost Co, a South Korean biotechnology company, is expanding its cell and gene therapy contract development and manufacturing organization (CDMO)...
Oct 18, 2022 (Gmt+09:00)
-
Bio & Pharma
Medipost acquires Canada’s OmniaBio for CDMO business
Medipost Co., a South Korean biotechnology company, has acquired a 39.6% stake in OmniaBio Inc., a Canada-based cell and gene therapy contract devel...
May 31, 2022 (Gmt+09:00)
-
Korean startups
Private equity consortium buys 30% stake in biotech firm Medipost
South Korea’s first generation biotech firm Medipost Co. will sell a 30% stake to a private equity consortium, the company announced after W...
Mar 17, 2022 (Gmt+09:00)